BACKGROUND: Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectable high-density lipoprotein cholesterol (HDL-C) levels and by early adulthood develop many manifestations of the disorder, including corneal opacities, anemia, and renal disease. OBJECTIVE: To determine if infusions of recombinant human LCAT (rhLCAT) could reverse the anemia, halt progression of renal disease, and normalize HDL in FLD. METHODS: rhLCAT (ACP-501) was infused intravenously over 1 hour on 3 occasions in a dose optimization phase (0.3, 3.0, and 9.0 mg/kg), then 3.0 or 9.0 mg/kg every 1 to 2 weeks for 7 months in a maintenance phase. Plasma lipoproteins, lipids, LCAT levels, and several measures of renal function and other clinical labs were monitored. RESULTS: LCAT concentration peaked at the end of each infusion and decreased to near baseline over 7 days. Renal function generally stabilized or improved and the anemia improved. After infusion, HDL-C rapidly increased, peaking near normal in 8 to 12 hours; analysis of HDL particles by various methods all revealed rapid sequential disappearance of preβ-HDL and small α-4 HDL and appearance of normal α-HDL. Low-density lipoprotein cholesterol increased more slowly than HDL-C. Of note, triglyceride routinely decreased after meals after infusion, in contrast to the usual postprandial increase in the absence of rhLCAT infusion. CONCLUSIONS: rhLCAT infusions were well tolerated in this first-in-human study in FLD; the anemia improved, as did most parameters related to renal function in spite of advanced disease. Plasma lipids transiently normalized, and there was rapid sequential conversion of small preβ-HDL particles to mature spherical α-HDL particles. Published by Elsevier Inc.
BACKGROUND:Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectable high-density lipoprotein cholesterol (HDL-C) levels and by early adulthood develop many manifestations of the disorder, including corneal opacities, anemia, and renal disease. OBJECTIVE: To determine if infusions of recombinant humanLCAT (rhLCAT) could reverse the anemia, halt progression of renal disease, and normalize HDL in FLD. METHODS: rhLCAT (ACP-501) was infused intravenously over 1 hour on 3 occasions in a dose optimization phase (0.3, 3.0, and 9.0 mg/kg), then 3.0 or 9.0 mg/kg every 1 to 2 weeks for 7 months in a maintenance phase. Plasma lipoproteins, lipids, LCAT levels, and several measures of renal function and other clinical labs were monitored. RESULTS:LCAT concentration peaked at the end of each infusion and decreased to near baseline over 7 days. Renal function generally stabilized or improved and the anemia improved. After infusion, HDL-C rapidly increased, peaking near normal in 8 to 12 hours; analysis of HDL particles by various methods all revealed rapid sequential disappearance of preβ-HDL and small α-4 HDL and appearance of normal α-HDL. Low-density lipoprotein cholesterol increased more slowly than HDL-C. Of note, triglyceride routinely decreased after meals after infusion, in contrast to the usual postprandial increase in the absence of rhLCAT infusion. CONCLUSIONS: rhLCAT infusions were well tolerated in this first-in-human study in FLD; the anemia improved, as did most parameters related to renal function in spite of advanced disease. Plasma lipids transiently normalized, and there was rapid sequential conversion of small preβ-HDL particles to mature spherical α-HDL particles. Published by Elsevier Inc.
Authors: V Panescu; Y Grignon; D Hestin; G Rostoker; L Frimat; E Renoult; J Gamberoni; G Grignon; M Kessler Journal: Nephrol Dial Transplant Date: 1997-11 Impact factor: 5.992
Authors: Bijan Roshan; Om P Ganda; Ranil Desilva; Rose B Ganim; Edmund Ward; Sarah D Haessler; Eliana Y Polisecki; Bela F Asztalos; Ernst J Schaefer Journal: J Clin Lipidol Date: 2011-08-23 Impact factor: 4.766
Authors: Masato Nishiwaki; Katsunori Ikewaki; Giovanni Bader; Hassan Nazih; Minna Hannuksela; Alan T Remaley; Robert D Shamburek; H Bryan Brewer Journal: Arterioscler Thromb Vasc Biol Date: 2006-03-16 Impact factor: 8.311
Authors: Bela F Asztalos; Ernst J Schaefer; Katalin V Horvath; Shizuya Yamashita; Michael Miller; Guido Franceschini; Laura Calabresi Journal: J Lipid Res Date: 2006-12-20 Impact factor: 5.922
Authors: Lita A Freeman; Robert D Shamburek; Maureen L Sampson; Edward B Neufeld; Masaki Sato; Sotirios K Karathanasis; Alan T Remaley Journal: J Lipid Res Date: 2019-02-26 Impact factor: 5.922
Authors: Allison B Andraski; Sasha A Singh; Lang Ho Lee; Hideyuki Higashi; Nathaniel Smith; Bo Zhang; Masanori Aikawa; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2019-09-26 Impact factor: 8.311
Authors: Boris L Vaisman; Edward B Neufeld; Lita A Freeman; Scott M Gordon; Maureen L Sampson; Milton Pryor; Emily Hillman; Milton J Axley; Sotirios K Karathanasis; Alan T Remaley Journal: J Pharmacol Exp Ther Date: 2018-12-18 Impact factor: 4.030
Authors: Kelly A Manthei; Shyh-Ming Yang; Bolormaa Baljinnyam; Louise Chang; Alisa Glukhova; Wenmin Yuan; Lita A Freeman; David J Maloney; Anna Schwendeman; Alan T Remaley; Ajit Jadhav; John Jg Tesmer Journal: Elife Date: 2018-11-27 Impact factor: 8.140
Authors: Ernst J Schaefer; Pimjai Anthanont; Margaret R Diffenderfer; Eliana Polisecki; Bela F Asztalos Journal: Prog Cardiovasc Dis Date: 2016-08-24 Impact factor: 8.194
Authors: Andrew S Geller; Eliana Y Polisecki; Margaret R Diffenderfer; Bela F Asztalos; Sotirios K Karathanasis; Robert A Hegele; Ernst J Schaefer Journal: J Lipid Res Date: 2018-10-17 Impact factor: 5.922
Authors: Lita A Freeman; Stephen J Demosky; Monika Konaklieva; Rostislav Kuskovsky; Angel Aponte; Alice F Ossoli; Scott M Gordon; Ross F Koby; Kelly A Manthei; Min Shen; Boris L Vaisman; Robert D Shamburek; Ajit Jadhav; Laura Calabresi; Marjan Gucek; John J G Tesmer; Rodney L Levine; Alan T Remaley Journal: J Pharmacol Exp Ther Date: 2017-06-02 Impact factor: 4.030